Drugs / JNJ-75105186
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05159128 | Nov 2021 → Apr 2022 | — | Janssen Pharmaceutical K.K. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-75105186 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05159128 ↗ |
| Route | Oral | “JNJ-75105186 will be administered orally in Part 1 and 2.” NCT05159128 ↗ |